C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function: Report of an ADA Workshop, 21-22 October 2001

Diabetes

Volumn 53, Issue 1, 2004, Pages 250-264

  Palmer, Jerry P ^a,b   Fleming, G Alexander ^c   Greenbaum, Carla J ^d   Herold, Kevan C ^e   Jansa, Lisa D ^c   Kolb, Hubert ^f   Lachin, John M ^g   Polonsky, Kenneth S ^h   Pozzilli, Paolo ⁱ   Skyler, Jay S ^j   Steffes, Michael W ^k  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Puget Sound Health Care System   (United States)

^c Kinexum   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e Howard Hughes Medical Institute   (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; HEMOGLOBIN A1C;

ADULT; BLOOD GLUCOSE MONITORING; CELL PROTECTION; CONFERENCE PAPER; CONTROLLED STUDY; DIABETOGENESIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; GLYCEMIC INDEX; HUMAN; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; MEDICAL SOCIETY; OUTCOMES RESEARCH; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

C-PEPTIDE; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 9144268894     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.1.250     Document Type: Conference Paper

References (115)

1. Atkinson MA, Leiter EH: The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med Rev 5:601-604, 1999
2. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685-1693, 2002
3. The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group: Intervening before the onset type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial. Diabetologia 46:339-346, 2003
4. Assan R, Feutren G, Sirmai J, Laborie C, Boitard C, Vexiau P, Du Rostu H, Rodier M, Figoni M, Vague P, Hors J, Bach J-F: Plasma C-peptide levels and clinical remissions in recent-onset type 1 diabetic patients treated with cyclosporin A and insulin. Diabetes 36:768-774, 1990
5. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S: Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319:599-604, 1988
6. Herold KC, Hagopian W: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698, 2002
7. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR: β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet 358:1749-1753, 2001
8. The DCCT Research Group: Effect of intensive therapy on residual β-cell function in patients with type I diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 128:517-523, 1998
9. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:997-986, 1993
10. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
11. Bonifacio E, Scirpoil M, Kredel K, Füchtenbusch M, Ziegler A-G: Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 163:525-532, 1999
12. Füchtenbusch M, Kredel K, Bonifacio E, Schnell O, Ziegler A-G: Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens. Diabetes 49:918-925, 2000
13. Greeley SA, Katsumata M, Yu L, Eisenbarth G, Moore D, Goodarzi H, Barker C, Naji A, Noorchashm H: Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 8:399-402, 2002
14. Noorchashm H, Noorchashm N, Kem J, Rostami SY, Barker CF, Naji A: B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46:941-946, 1997
15. Reijonen H, Daniels TL, Lernmark Å, Nepom GT: GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 49:1621-1626, 2000
16. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS: Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 88:103-108, 2003
17. Jaeger C, Allendorfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federlin K, Bretzler RG: Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 29:510-515, 1997
18. Yokota I, Matsuda J, Naito E, Ito M, Shima K, Kuroda Y: Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. Diabetes Care 21:49-52, 1998
19. Decochez K, Keymuelen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C, Rottiers R, Winnock F, Ver Elst K, Weets I, Kaufman L, Pipeleers D, Gorus FK, The Belgian Diabetes Registry: Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Diabetes Care 23:1072-1078, 2000
20. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK: High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type I diabetes presenting before 40 years of age. Diabetes Care 23:838-844, 2000
21. Petersen JS, Dyrberg T, Karlsen AE, Møvig J, Michelsen B, Nerup J, Mandrup-Poulsen T, The Canadian-European Randomized Control Trial Group: Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of β-cell function and remission in recent-onset IDDM after cyclosporin treatment. Diabetes 43:1291-1296, 1994
22. Bosi E, Braghi S, Maffi P, Scirpoli M: Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 50:2464-2471, 2001
23. Jaeger C, Brendel MD, Eckhard M, Bretzel RG: Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes 108:328-333, 2000
24. Tyden G, Reinholt FP, Sundkvist G, Bolinder J: Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 335:860-863, 1996
25. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin, JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF: Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318:663-670, 1988
26. Dupre J, Mahon JL: Diabetes-related autoantibodies and the selection of subjects for trials of therapies to preserve pancreatic β-cell function in recent-onset type 1 diabetes. Diabetes Care 23:1057-1058, 2000
27. Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler A-G: Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 41:536-541, 1998
28. Roep BO, Atkinson M, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA: Autoreactive T cell responses in insulin-dependent (type 1) diabetes: report of the first international workshop for standardization of T cell assays. J Autoimmun. 13:267-282, 1999
29. Kaufman DL, Tisch R, Sarvetnick N, Chatenoud L: Report from the 1st International NOD Mouse T-Cell Workshop and the follow-up mini-workshop. Diabetes 50:2459-2463, 2001
30. Karlsson MG, Lawesson SS, Ludvigsson J: Th1-like dominance in high-risk first-degree relatives of type I diabetic patients. Diabetologia 43:742-749, 2000
31. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A: A disease-associated cellular immune response in type 1 diabetics to immunodominant epitope of insulin. J Clin Invest 107:173-180, 2001
32. Nepom GT, Buckner JH, Novak EJ, Reichstetter S, Reijonen H, Gebe J, Wang R, Swanson E, Kwok WW: HLA class II tetramers: tools for direct analysis of antigen-specific CD4+ T cells. Arthritis Rheum 46:5-12, 2002
33. Polonsky KS, Jaspan J, Pugh W, Cohen D, Schneider M, Schwartz T, Moossa AR, Tager H, Rubenstein AH: Metabolism of C-peptide in the dog: in vivo demonstration of the absence of hepatic extraction. J Clin Invest 72:1114-1123, 1983
34. Polonsky KS, Pugh W, Jaspan JB, Cohen DM, Karrison T, Tager HS, Rubenstein AH: C-peptide and insulin secretion: relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest 74:1821-1829, 1984
35. Bratusch-Marrain PR, Waldhausl WK, Gasic S, Hofer A: Hepatic disposal of biosynthetic human insulin and porcine proinsulin in humans. Metabolism 33:151-157, 1984
36. Licinio-Paixao J, Polonsky KS, Given BD, Pugh W, Ostrega D, Frank BF, Rubenstein AH: Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. J Clin Endocrinol Metab 63:401-403, 1986
37. Gumbiner B, Polonsky KS, Beltz WF, Griver K, Wallace P, Brechtel G, Henry RR: Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 70:1594-1602, 1990
38. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH, Rossing N: Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 62:197-203, 1978
39. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 77:98-105, 1986
40. Shapiro ET, Tillil H, Rubenstein AH, Polonsky KS: Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab 67:1094-1099, 1988
41. Eaton RP, Allen RC, Shade DS, Erickson KM, Standefer J: Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 51:520-528, 1980
42. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377, 1992
43. Nakanishi K, Kobayashi T, Miyashita H, Ohkubo M, Sugimoto T, Murase T, Kosaka K, Inouye K, Kono M: Relationships among islet cell antibodies, residual β-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Metabolism 39:925-930, 1990
44. Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K: Residual β-cell function and HLA-A24 in IDDM, markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334-1339, 1995
45. Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Öster J: Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:208-213, 1987
46. Ludvigsson J, Heding LG, Larsson Y, Leander E: C-peptide in juvenile diabetics beyond the postinitial remission period. Acta Pædiatr Scand 66:177-184, 1977
47. Madsbad S, McNair P, Faber OK, Binder C, Christiansen C, Transbøl I: β-Cell function and metabolic control in insulin treated diabetics. Acta Endocrinologica 93:196-200, 1980
48. Sjöberg S, Gjötterberg M, Berglund L, Möller E, Österman J: Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type 1 (insulin-dependent) diabetes mellitus. J Diabet Complications 1:18-22, 1991
49. Grajwer LA, Pildes RS, Horwitz DL, Rubenstein AH: Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. J Pediatr 90:42-48, 1977
50. Gonen B, Goldman J, Baldwin D, Goldberg RB, Ryan WG, Blix PM, Schanzlin D, Fritz KJ, Rubenstein AH: Metabolic control in diabetic patients: effect of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin antibodies. Diabetes 28:749-753, 1979
51. Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, Shima K: Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control. Diabetes 37:81-88, 1988
52. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J: Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181-189, 2000
53. The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 65:30-36, 1987
54. Steffes MW, Sibley S, Jackson M, Thomas W: β-Cell function and the development of diabetes-related related complications in the Diabetes Control and Complications Trial. Diabetes Care 26:832-836, 2003
55. Hamilton DV, Mundia SS, Lister J: Mode of presentation of juvenile diabetes. Br Med J 2:211-212, 1976
56. Pinkey JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EA: Presentation and progress of childhood diabetes mellitus: a prospective population-based study: The Bart's-Oxford Study Group. Diabetologia 37:70-74, 1994
57. Pozzilli P, Visalli N, Buzzetti R, IMDIAB Group: Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population based study. Metabolism 47:1205-1210, 1998
58. Knip M, Ilonen J, Mustonen A, Akerblom HK: Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4. Diabetologia 29:347, 1986
59. Snorgaard O, Larsen LH, Binder C: Homogeneity in pattern of decline of β-cell function in IDDM. Diabetes Care 15:1009-1015, 1992
60. Pozzilli P, Mesturino C, Crinò A, Gross T, Jeng L, Visalli N, IMDIAB Group: Is the process of beta cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males? European J Endoc 145:1-5, 2001
61. Shah SC, Malone JI, Simpson NE: A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes. New Engl J Med 350:550-555, 1989
62. Pozzilli P, Browne P, Kolb H: Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM: the Nicotinamide Trialists. Diabetes Care 19:1357-1363, 1996
63. Pozzilli P, Maclaren NK: Immunotherapy at clinical diagnosis of insulin dependent diabetes: an approach still worth considering. Trends Endocrinol Metab 4:101-105, 1993
64. Skyler JS, Marks JB: Immune intervention in type 1 diabetes mellitus. Diabetes Rev 1:15-42, 1993
65. Abiru N, Takino H, Yano M, Kawasaki E, Yamasaki H, Yamaguchi Y, Akazawa S, Nagataki S: Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. J Autoimmmun 9:683-688, 1996
66. Carlsson A, Sundkvist G, Groop L, Tuomi T: Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85:76-80, 2000
67. Desailloud R, Fajardy I, Vambergue A, Prevost G, Pigny P, Fontaine P: Autoimmune markers in slow type 1 diabetes: confrontation to type 1 diabetes. Diabetes Metab 26:353-360, 2000
68. Falorni A, Gambelunghe G, Forini F, Kassi G, Cosentino A, Candeloro P, Bolli GB, Brunetti P, Calcinaro F: Antoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 85:309-316, 2000
69. Fukui M, Nakano K, Shigeta H, Yoshimori K, Fujii M, Kitagawa Y, Mori H, Kajiyama S, Nakamura N, Abe N, Obayashi H, Fukui I, Ohta K, Ohta M, Kondo M: Antibodies to ghitamic acid decarboxylase in Japanese diabetic patients with secondary failure of oral hypoglycaemic therapy. Diabetic Med 14:148-152, 1997
70. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, Brunetti P, Sanjeevi CB, Falorni A: Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol 52:565-573, 2000
71. Goetz FC, Roel J, Jacobs DR Jr, Barbosa J, Hannan P, Palmer J, Hagopian W: Declining beta-cell function in type 2 diabetes: 5-year follow-up and immunologic studies of the population of Wadena, MN. Metabolism 51:144-148, 2002
72. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark Å, Sundkvist G: β-Cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910, 1993
73. Gottsäter A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G, Hagopian WA: Glutamate decarboxylase antibody levels predict rate of β-Cell decline in adult-onset diabetes. Diabetes Res Clin Pract 27:133-140, 1995
74. Gray RS, Irvine WJ, Cameron EH, Duncan LJ: Glucose and insulin responses to oral glucose in overt non-insulin-dependent diabetics with and without the islet cell antibody. Diabetes 29:312-316, 1980
75. Groop LC, Bottazzo GF, Doniach D: Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 35:237-241, 1986
76. Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L, Grosz A, Gero L, Madacsy L, Romics L, Karadi I, Fust G, Panczel P: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457, 2003
77. Inukai T, Fujiwara Y, Tayama K, Aso Y, Ogino K, Takemura Y: Clinical characteristics of patients with the initial diagnosis of NIDDM with positivity for antibodies to glutamic acid dicarboxylase. Exp Clin Endocrinol Diabetes 105:327-330, 1997
78. Isomaa B, Almgren P, Henricsson M, Taskinen M-R, Tuomi T, Groop LC, Sarelin L: Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 22:1347-1353, 1999
79. Kasuga A, Maruyama T, Ozawa Y, Takei I, Falorni A, Lernmark Å, Saruta T: Antibody to the M(r) 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin-dependent diabetes in Japanese. J Autoimmun 9:105-111, 1996
80. Kobayashi T, Nakanishi K, Sugimoto T, Itoh T, Murase T, Kosaka K, Tsuji K: Maleness as risk factor for slowly progressive IDDM. Diabetes Care 12:7-11, 1989
81. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622-626, 1996
82. Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K: Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes 36:510-517, 1987
83. Landin-Olsson M: Latent autoimmune diabetes in adults. Ann N Y Acad Sci 958:112-116, 2002
84. Maruyama T, Kasuga A, Ozawa Y, Nagata A, Abiko F, Suzuki Y, Saruta T: Glutamic acid decarboxylase 65 (GAD65) antibodies and insulin autoantibodies in Japanese patients with non-insulin-dependent diabetes mellitus. Endocr J 44:43-51, 1997
85. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MIJ: GAD antibodies in NIDDM: ten-year follow-up from the diagnosis. Diabetes Care 18:1557-1565, 1995
86. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M: Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 49:32-38, 2000
87. Rattarasarn C, Aguilar Diosdado M, Soonthornpun S: Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand. Diabetes Res Clin Pract 37:193-197, 1997
88. Takino H, Yamasaki H, Sera Y, Abe T, Ozaki M, Kondo H, Sakamaki H, Kawasaki E, Yamaguchi Y, Nagataki S, Eguchi K: The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab Rev 14:334-335, 1998
89. Törn C, Landin-Olsson M, Östman J, Schersten B, Arnqvist H, Blohme G, Björk E, Bolinder J, Eriksson J, Littorin B, Nyström L, Sundkvist G, Lernmark Å: Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442-447, 2000
90. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of diabetes. Diabetes 42:359-362, 1993
91. Tuomi T, Carlsson AL, Li H, Isomaa B, Miettinen A, Nilsson A, Nissén M, Ehrenström B-O, Forsén B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen M-R, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157, 1999
92. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes: UK Prospective Diabetes Study Group. Lancet 350:1288-1293, 1997
93. Willis JA, Scott RS, Brown LJ, Forbes LV, Schmidli RS, Zimmet PZ, Mackay IR, Rowley MJ: Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Res Clin Pract 33:89-97, 1996
94. Wrobelewski M, Gottsäter A, Lindgarde F, Fernlund P, Sundkvist G: Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes 21:250-255, 1998
95. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I: Crucial points at diagnosis: type 2 diabetes or slow type 1 diabetes. Diabetes Care 22 (Suppl. 2):B59-B64, 1999
96. Brunzell JD, Robertson RP, Lerner RL: Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-227, 1976
97. Bardet S, Rohmer V, Maugendre D, Marre M, Semana G, Limal JM, Allannic H, Charbonnel B, Sai P: Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:648-654, 1991
98. Chaillous L, Rohmer V, Maugendre D, Lecomte P, Marechaud R, Marre M, Guilhem I, Charbonnel B, Sai P: Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus. Metabolism 45:306-314, 1996
99. Menchini M, Meschi F, Lambiase R, Puzzovio M, Del Guercio MJ, Chiumello G: C-peptide response to arginine stimulation in diabetic children. J Pediatr 96:362-366, 1980
100. Palmer JP, Benson JW, Walter RM, Ensinck JW: Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest 58:565-570, 1976
101. Tominaga M, Komiya I, Johnson JH: Loss of insulin response to glucose but not arginine during the development of autoimmune diabetes in BB/W rats: relationships to islet volume and glucose transport rate. Proc Natl Acad Sci U S A 83:979-9753, 1986
102. Madsbad S, Sauerbrey N, Moller-Jensen B, Krarup T, Kuhl C: Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Acta Med Scand 222:71-74, 1987
103. Ronnemaa T: Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Lab Invest 46:345-349, 1986
104. Greenbaum CJ, Harrison LC: Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52:1059-1065, 2003
105. Schnell O, Eisfelder B, Standl E, Ziegler AG: High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 46:1607-1611, 1997
106. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Marechaud R, Bougneres P, Charbonnel B, Sai P: Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial: Diabete Insuline Orale group. Lancet 356:545-549, 2000
107. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
108. Greenbaum CJ: Insulin Resistance in type 1 Diabetes. Diabete Metab Res Rev 18:192-200, 2002
109. Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79:790-800, 1987
110. Bergman RN: Lilly Lecture 1989: Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 38:1512-27, 1989
111. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
112. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C: Oral glucose tolerance test minimal model indexes of β-cell function and insulin sensitivity. Diabetes 50:150-158, 2001
113. Caumo A, Bergman RN, Cobelli C: Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J Clin Endocrinol Metab 85:4396-4402, 2000
114. Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, Cobelli C: Quantitative indexes of beta-cell function during graded up & down glucose infusion from C-peptide minimal models. Am J Physiol 280:E2-E10, 2001
115. Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 2:93-113, 1981